B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
STOK
Stoke TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+80.4
Score
AI commentary
The confirmed company Q2 update is constructive on EMPEROR enrollment, cash runway, and regulatory preparation, but it does not establish a Phase 3 efficacy surprise and the pivotal readout remains distant. No trustworthy post-print price reaction, analyst target change, estimate revision, or social signal is available in the packet. The evidence supports cautious monitoring rather than a stronger post-earnings directional thesis.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-11-11eventPost-earnings update: EMPEROR enrollment complete and regulatory path advancesHigh impact
The company’s August 3 Q2 business update reported completion of enrollment for 162 patients in the Phase 3 EMPEROR study, with a data readout anticipated in Q3 2027. Stoke expects a pre-NDA meeting with the FDA in H2 2026 and plans to initiate a rolling U.S. NDA in Q1 2027. Pro forma cash of approximately $420 million is expected to fund operations toward potential early-2028 commercialization. [#SEC-8K-2026-08-03]
2026-11-11catalystBinary Phase 3 and regulatory execution riskHigh impact
EMPEROR remains blinded and pivotal efficacy data are not expected until Q3 2027. The investment case depends on controlled Phase 3 results validating earlier open-label data, successful FDA alignment, and timely NDA execution. [#SEC-8K-2026-08-03]
2027-08-13catalystSTK-002 ADOA development milestoneHigh impact
Dose escalation is continuing in the Phase 1 OSPREY study of STK-002, with initial safety and efficacy data anticipated in H1 2027. The program provides platform and pipeline optionality but remains early stage. [#SEC-8K-2026-08-03]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology